BMRA vs. CARA, COCP, TENX, XCUR, ATHA, GOVX, MIRA, BTAI, CYTH, and APRE
Should you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Cara Therapeutics (CARA), Cocrystal Pharma (COCP), Tenax Therapeutics (TENX), Exicure (XCUR), Athira Pharma (ATHA), GeoVax Labs (GOVX), MIRA Pharmaceuticals (MIRA), BioXcel Therapeutics (BTAI), Cyclo Therapeutics (CYTH), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry.
Biomerica vs.
Biomerica (NASDAQ:BMRA) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.
Cara Therapeutics has a consensus target price of $27.84, indicating a potential upside of 481.21%. Given Cara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cara Therapeutics is more favorable than Biomerica.
Cara Therapeutics received 530 more outperform votes than Biomerica when rated by MarketBeat users. Likewise, 72.50% of users gave Cara Therapeutics an outperform vote while only 67.82% of users gave Biomerica an outperform vote.
Biomerica has a net margin of -100.52% compared to Cara Therapeutics' net margin of -1,099.76%. Biomerica's return on equity of -90.19% beat Cara Therapeutics' return on equity.
In the previous week, Biomerica had 10 more articles in the media than Cara Therapeutics. MarketBeat recorded 11 mentions for Biomerica and 1 mentions for Cara Therapeutics. Cara Therapeutics' average media sentiment score of 0.50 beat Biomerica's score of 0.36 indicating that Cara Therapeutics is being referred to more favorably in the news media.
22.3% of Biomerica shares are owned by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are owned by institutional investors. 15.0% of Biomerica shares are owned by insiders. Comparatively, 3.1% of Cara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Biomerica has higher earnings, but lower revenue than Cara Therapeutics. Biomerica is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Biomerica has a beta of -1.04, indicating that its stock price is 204% less volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.
Summary
Cara Therapeutics beats Biomerica on 9 of the 17 factors compared between the two stocks.
Get Biomerica News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biomerica Competitors List
Related Companies and Tools
This page (NASDAQ:BMRA) was last updated on 1/21/2025 by MarketBeat.com Staff
